TWI619729B - 抗－ｈｌａ－ｂ*２７抗體及其用途 - Google Patents

抗－ｈｌａ－ｂ*２７抗體及其用途 Download PDF

Info

Publication number
TWI619729B
TWI619729B TW102111629A TW102111629A TWI619729B TW I619729 B TWI619729 B TW I619729B TW 102111629 A TW102111629 A TW 102111629A TW 102111629 A TW102111629 A TW 102111629A TW I619729 B TWI619729 B TW I619729B
Authority
TW
Taiwan
Prior art keywords
hla
synthesis
artificial sequence
antibody
dna
Prior art date
Application number
TW102111629A
Other languages
English (en)
Chinese (zh)
Other versions
TW201343675A (zh
Inventor
安德魯 墨菲
安娜 科斯蒂克
Original Assignee
再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 再生元醫藥公司 filed Critical 再生元醫藥公司
Publication of TW201343675A publication Critical patent/TW201343675A/zh
Application granted granted Critical
Publication of TWI619729B publication Critical patent/TWI619729B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW102111629A 2012-04-02 2013-04-01 抗－ｈｌａ－ｂ*２７抗體及其用途 TWI619729B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261618969P 2012-04-02 2012-04-02
US61/618,969 2012-04-02
US201361778703P 2013-03-13 2013-03-13
US61/778,703 2013-03-13

Publications (2)

Publication Number Publication Date
TW201343675A TW201343675A (zh) 2013-11-01
TWI619729B true TWI619729B (zh) 2018-04-01

Family

ID=48093122

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102111629A TWI619729B (zh) 2012-04-02 2013-04-01 抗－ｈｌａ－ｂ*２７抗體及其用途

Country Status (22)

Country Link
US (1) US9790273B2 (enExample)
EP (1) EP2834272B1 (enExample)
JP (1) JP6320993B2 (enExample)
KR (1) KR20150003256A (enExample)
CN (1) CN104169302A (enExample)
AR (1) AR090585A1 (enExample)
AU (1) AU2013243644C1 (enExample)
BR (1) BR112014024622A2 (enExample)
CA (1) CA2868907C (enExample)
CL (1) CL2014002631A1 (enExample)
CO (1) CO7121320A2 (enExample)
EA (1) EA201491827A1 (enExample)
HK (1) HK1207092A1 (enExample)
IL (2) IL234707A0 (enExample)
MX (1) MX365690B (enExample)
MY (1) MY171180A (enExample)
NZ (1) NZ700650A (enExample)
PH (1) PH12014502184A1 (enExample)
SG (2) SG10201608136SA (enExample)
TW (1) TWI619729B (enExample)
UY (1) UY34721A (enExample)
WO (1) WO2013152001A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
EP2877580B1 (en) 2012-07-27 2019-01-30 City of Hope An mva vaccine for delivery of a ul128 complex and preventing cmv infection
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
SG10201710322VA (en) * 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA2973641A1 (en) * 2015-02-04 2016-08-11 Universitat Zurich Use of hla-b27 homodimers for cancer treatment
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US10900965B2 (en) 2015-08-24 2021-01-26 University Of Cincinnati Methods and compositions for the detection of Fc receptor binding activity of antibodies
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
PL3390442T3 (pl) * 2015-12-18 2024-03-18 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
EP3390443A4 (en) * 2015-12-18 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3426681B1 (en) 2016-03-08 2020-08-26 Universität Zürich Hla-b57 open conformers
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3496749B9 (en) 2016-08-10 2023-10-04 Universität Zürich Mhc class ia open conformers
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
US20200114022A1 (en) 2017-03-31 2020-04-16 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN108486226B (zh) * 2018-04-01 2022-04-12 广东辉锦创兴生物医学科技有限公司 Hla-b27等位基因的检测试剂盒及其应用
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
CA3133419A1 (en) * 2019-03-21 2020-09-24 Gamida Cell Ltd. Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
CN111175490A (zh) * 2020-01-19 2020-05-19 泛肽生物科技(浙江)有限公司 一种定性检测hla-b27的试剂盒及其检测方法
WO2022216832A1 (en) * 2021-04-07 2022-10-13 Regeneron Pharmaceuticals, Inc. A composition for use in treating mhc-1-opathies
MX2024004558A (es) * 2021-10-14 2024-07-10 Regeneron Pharma Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1).
WO2023220263A1 (en) * 2022-05-13 2023-11-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for modulating tcr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213824A2 (en) * 1985-08-16 1987-03-11 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant-B27

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369010A (en) 1985-08-16 1994-11-29 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant -B27
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US20130315933A1 (en) 2010-10-06 2013-11-28 Christoph Renner Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213824A2 (en) * 1985-08-16 1987-03-11 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant-B27

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
2003年07月，Levering, W.H.B.M., et al., A.C.," Flow Cytometric HLA-B27 Screening: Cross-Reactivity Patterns of Commercially Available Anti–HLA-B27 Monoclonal Antibodies With Other HLA-B Antigens", Cytometry B Clin. Cytom., 2003, Vol.54, Issue 1, P.28-38.
年07月，Levering, W.H.B.M., et al., A.C.," Flow Cytometric HLA-B27 Screening: Cross-Reactivity Patterns of Commercially Available Anti–HLA-B27 Monoclonal Antibodies With Other HLA-B Antigens", Cytometry B Clin. Cytom., 2003, Vol.54, Issue 1, P.28-38. *

Also Published As

Publication number Publication date
BR112014024622A2 (pt) 2017-08-08
AU2013243644A1 (en) 2014-10-23
CA2868907A1 (en) 2013-10-10
WO2013152001A3 (en) 2013-12-27
SG10201608136SA (en) 2016-11-29
US20130259876A1 (en) 2013-10-03
MX2014011898A (es) 2014-11-12
US9790273B2 (en) 2017-10-17
MX365690B (es) 2019-06-11
PH12014502184A1 (en) 2014-12-10
KR20150003256A (ko) 2015-01-08
UY34721A (es) 2013-10-31
EA201491827A1 (ru) 2015-03-31
EP2834272A2 (en) 2015-02-11
NZ700650A (en) 2017-02-24
CN104169302A (zh) 2014-11-26
CA2868907C (en) 2022-01-04
AU2013243644B2 (en) 2018-02-08
TW201343675A (zh) 2013-11-01
SG11201405759UA (en) 2014-11-27
EP2834272B1 (en) 2020-06-24
IL234707A0 (en) 2014-11-30
MY171180A (en) 2019-09-30
CO7121320A2 (es) 2014-11-20
JP6320993B2 (ja) 2018-05-09
AU2013243644C1 (en) 2018-05-10
CL2014002631A1 (es) 2015-01-16
JP2015514110A (ja) 2015-05-18
WO2013152001A2 (en) 2013-10-10
AR090585A1 (es) 2014-11-26
IL256716A (en) 2018-03-29
HK1207092A1 (en) 2016-01-22

Similar Documents

Publication Publication Date Title
JP6320993B2 (ja) 抗ｈｌａ−ｂ＊２７抗体およびその使用
AU2019307928B2 (en) Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof
TWI728990B (zh) 抗ｐｓｍａ抗體，結合ｐｓｍａ與ｃｄ３之雙特異性抗原結合分子，及其用途
AU2011312623B2 (en) Anti-CD48 antibodies and uses thereof
TWI591073B (zh) 抗－ａｓｉｃ１抗體及其用途
TW201418282A (zh) 抗ｃｄ-３抗體，結合至ｃｄ３及ｃｄ２０的雙專一性抗原結合分子，及其用途
TW201622745A (zh) 用於腫瘤治療之方法及抗體組成物
JP2017533888A (ja) 抗ｉｌ−２５抗体およびその使用
JP7541167B2 (ja) 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
US9371383B2 (en) Anti-ASIC1 antibodies and uses thereof
KR20150084007A (ko) 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
US9533039B2 (en) Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees